Gerecitano J - Search Results

1

Transcriptional basis for the differences in inducible nitric oxide synthase (iNOS) expression between nonmetastatic and metastatic murine melanoma cell lines.

Gerecitano J, Perle MA, Vilcek J. Gerecitano J, et al. J Interferon Cytokine Res. 1999 Apr;19(4):393-405. doi: 10.1089/107999099314108. J Interferon Cytokine Res. 1999. PMID: 10334391

2

Requirement for transcription factor IRF-1 in NO synthase induction in macrophages.

Kamijo R, Harada H, Matsuyama T, Bosland M, Gerecitano J, Shapiro D, Le J, Koh SI, Kimura T, Green SJ, et al. Kamijo R, et al. Among authors: gerecitano j. Science. 1994 Mar 18;263(5153):1612-5. doi: 10.1126/science.7510419. Science. 1994. PMID: 7510419

3

Biological functions of IFN-gamma and IFN-alpha/beta: lessons from studies in gene knockout mice.

Kamijo R, Shapiro D, Gerecitano J, Le J, Bosland M, Vilcek J. Kamijo R, et al. Among authors: gerecitano j. Hokkaido Igaku Zasshi. 1994 Nov;69(6):1332-8. Hokkaido Igaku Zasshi. 1994. PMID: 7705746

4

Mycobacterium bovis infection of mice lacking receptors for interferon-gamma or for transcription factor IRF-1.

Kamijo R, Shapiro D, Gerecitano J, Le J, Bosland M, Vilcek J. Kamijo R, et al. Among authors: gerecitano j. J Interferon Res. 1994 Oct;14(5):281-2. doi: 10.1089/jir.1994.14.281. J Interferon Res. 1994. PMID: 7861030 No abstract available.

5

Generation of nitric oxide and clearance of interferon-gamma after BCG infection are impaired in mice that lack the interferon-gamma receptor.

Kamijo R, Gerecitano J, Shapiro D, Green SJ, Aguet M, Le J, Vilcek J. Kamijo R, et al. Among authors: gerecitano j. J Inflamm. 1995-1996;46(1):23-31. J Inflamm. 1995. PMID: 8832969

6

First-in-Class, First-in-Human Phase I Study of Selinexor, a Selective Inhibitor of Nuclear Export, in Patients With Advanced Solid Tumors.

Abdul Razak AR, Mau-Soerensen M, Gabrail NY, Gerecitano JF, Shields AF, Unger TJ, Saint-Martin JR, Carlson R, Landesman Y, McCauley D, Rashal T, Lassen U, Kim R, Stayner LA, Mirza MR, Kauffman M, Shacham S, Mahipal A. Abdul Razak AR, et al. Among authors: gerecitano jf. J Clin Oncol. 2016 Dec;34(34):4142-4150. doi: 10.1200/JCO.2015.65.3949. Epub 2016 Oct 31. J Clin Oncol. 2016. PMID: 26926685 Free PMC article. Clinical Trial.

7

A phase 1 dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzomib (PR-171) in patients with hematologic malignancies.

O'Connor OA, Stewart AK, Vallone M, Molineaux CJ, Kunkel LA, Gerecitano JF, Orlowski RZ. O'Connor OA, et al. Among authors: gerecitano jf. Clin Cancer Res. 2009 Nov 15;15(22):7085-91. doi: 10.1158/1078-0432.CCR-09-0822. Epub 2009 Nov 10. Clin Cancer Res. 2009. PMID: 19903785 Free PMC article. Clinical Trial.

8

Time to treatment response in patients with follicular lymphoma treated with bortezomib is longer compared with other histologic subtypes.

O'Connor OA, Portlock C, Moskowitz C, Hamlin P, Straus D, Gerecitano J, Gonen M, Dumitrescu O, Sarasohn D, Butos J, Neylon E, Mac-Gregor Cortelli B, Blumel S, Evens AM, Zelenetz AD, Wright J, Cooper B, Winter J, Vose J. O'Connor OA, et al. Among authors: gerecitano j. Clin Cancer Res. 2010 Jan 15;16(2):719-26. doi: 10.1158/1078-0432.CCR-08-2647. Epub 2010 Jan 12. Clin Cancer Res. 2010. PMID: 20068103 Clinical Trial.

9

Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity.

Wilson WH, O'Connor OA, Czuczman MS, LaCasce AS, Gerecitano JF, Leonard JP, Tulpule A, Dunleavy K, Xiong H, Chiu YL, Cui Y, Busman T, Elmore SW, Rosenberg SH, Krivoshik AP, Enschede SH, Humerickhouse RA. Wilson WH, et al. Lancet Oncol. 2010 Dec;11(12):1149-59. doi: 10.1016/S1470-2045(10)70261-8. Epub 2010 Nov 18. Lancet Oncol. 2010. PMID: 21094089 Free PMC article. Clinical Trial.

10

A Phase I trial of the kinesin spindle protein (Eg5) inhibitor AZD4877 in patients with solid and lymphoid malignancies.

Gerecitano JF, Stephenson JJ, Lewis NL, Osmukhina A, Li J, Wu K, You Z, Huszar D, Skolnik JM, Schwartz GK. Gerecitano JF, et al. Invest New Drugs. 2013 Apr;31(2):355-62. doi: 10.1007/s10637-012-9821-y. Epub 2012 May 22. Invest New Drugs. 2013. PMID: 22615058 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results